BioDelivery Sciences International Inc logo

BDSI - BioDelivery Sciences International Inc News Story

$3.22 0.1  2.2%

Last Trade - 12/05/21

Sector
Healthcare
Size
Small Cap
Market Cap £225.8m
Enterprise Value £198.9m
Revenue £113.3m
Position in Universe 4062nd / 6856

BRIEF-Biodelivery Sciences completes randomization in phase 3 trial of clonidine topical gel

Mon 8th December, 2014 12:00pm
Dec 8 (Reuters) - BioDelivery Sciences International Inc  BDSI.O : 
 * Announces completion of randomization in phase 3 trial of clonidine topical 
   gel for the treatment of painful diabetic neuropathy 
 * Says anticipates that topline results of the study will be available by the 
   end of March 2015 
 * Says bdsi plans to begin the second phase 3 study during the first quarter of 
   2015 
 
 * Source text for Eikon  ID:nPn3VbDzv  
 * Further company coverage  BDSI.O  ((Bengaluru Newsroom; +1 646 223 8780))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.